Cargando…
The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451929/ https://www.ncbi.nlm.nih.gov/pubmed/26038678 http://dx.doi.org/10.1186/1477-5956-12-43 |
_version_ | 1782374223428190208 |
---|---|
author | Laborde, Carlos M Alonso-Orgaz, Sergio Mourino-Alvarez, Laura Moreu, José Vivanco, Fernando Padial, Luis R Barderas, María G |
author_facet | Laborde, Carlos M Alonso-Orgaz, Sergio Mourino-Alvarez, Laura Moreu, José Vivanco, Fernando Padial, Luis R Barderas, María G |
author_sort | Laborde, Carlos M |
collection | PubMed |
description | BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understanding of the whole atherosclerotic process from atherogenesis to atherothrombosis. In this study, we conducted two different proteomic analyses of peripheral blood plasma from non-ST elevation acute coronary syndrome and ST elevation acute coronary syndrome patients vs healthy controls. RESULTS: Two-dimensional Fluorescence Difference in Gel Electrophoresis and mass spectrometry permitted the identification of 31 proteins with statistical differences (p < 0.05) between experimental groups. Additionally, validation by Western blot and Selected Reaction Monitoring permitted us to confirm the identification of a different and characteristic plasma proteomic signature for NSTEACS and STEACS patients. CONCLUSIONS: We purpose the severity of hypoxia as the cornerstone for explaining the differences observed between both groups. |
format | Online Article Text |
id | pubmed-4451929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44519292015-06-03 The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome Laborde, Carlos M Alonso-Orgaz, Sergio Mourino-Alvarez, Laura Moreu, José Vivanco, Fernando Padial, Luis R Barderas, María G Proteome Sci Research BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understanding of the whole atherosclerotic process from atherogenesis to atherothrombosis. In this study, we conducted two different proteomic analyses of peripheral blood plasma from non-ST elevation acute coronary syndrome and ST elevation acute coronary syndrome patients vs healthy controls. RESULTS: Two-dimensional Fluorescence Difference in Gel Electrophoresis and mass spectrometry permitted the identification of 31 proteins with statistical differences (p < 0.05) between experimental groups. Additionally, validation by Western blot and Selected Reaction Monitoring permitted us to confirm the identification of a different and characteristic plasma proteomic signature for NSTEACS and STEACS patients. CONCLUSIONS: We purpose the severity of hypoxia as the cornerstone for explaining the differences observed between both groups. BioMed Central 2014-10-10 /pmc/articles/PMC4451929/ /pubmed/26038678 http://dx.doi.org/10.1186/1477-5956-12-43 Text en © Laborde et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Laborde, Carlos M Alonso-Orgaz, Sergio Mourino-Alvarez, Laura Moreu, José Vivanco, Fernando Padial, Luis R Barderas, María G The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title | The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title_full | The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title_fullStr | The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title_full_unstemmed | The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title_short | The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
title_sort | plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451929/ https://www.ncbi.nlm.nih.gov/pubmed/26038678 http://dx.doi.org/10.1186/1477-5956-12-43 |
work_keys_str_mv | AT labordecarlosm theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT alonsoorgazsergio theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT mourinoalvarezlaura theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT moreujose theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT vivancofernando theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT padialluisr theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT barderasmariag theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT labordecarlosm plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT alonsoorgazsergio plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT mourinoalvarezlaura plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT moreujose plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT vivancofernando plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT padialluisr plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome AT barderasmariag plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome |